Tandem 2026: Key Advances in Cellular Therapy and Transplantation
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers: Serious safety concerns have led to a hold on the Lorigerlimab Trial, a critically important development in gynecologic cancers.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma: The focus shifts towards refining management strategies of inhibitor toxicities in the treatment of melanoma.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma: The SRN-101 has received fast-track designation from the FDA for treating recurrent high-grade glioma, marking a significant milestone.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma: A novel small molecule is showing promising early activity in the treatment of pretreated multiple myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC: A study comparing the quality of life outcomes using protons vs photons in OPSCC provides valuable insights for patients and clinicians.
